Lantern Pharma Inc.
LTRN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for LTRN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LTRN
Lantern Pharma Inc. (LTRN) is a clinical-stage biotechnology company focused on developing targeted cancer therapies using its proprietary AI-driven drug discovery platform, RADR®, with lead candidates LP-300, LP-184, and LP-284 in various stages of clinical development.
Key risk: Going concern uncertainty
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 3 clinical trials for Lantern Pharma Inc..
Similar companies
Lantern Pharma Inc. (LTRN) is a clinical-stage biotechnology company focused on developing targeted cancer therapies using its proprietary AI-driven drug discovery platform, RADR®, with lead candidates LP-300, LP-184, and LP-284 in various stages of clinical development.
- Lantern Pharma is advancing three lead drug candidates: LP-300, LP-184, and LP-284, targeting multiple cancer indications [sec_mda · as of 2026-05-15].
- The company utilizes its proprietary RADR® artificial intelligence platform to streamline drug discovery and development [sec_mda · as of 2026-03-30].
- As of June 30, 2026, Lantern Pharma reported cash and equivalents of $6.7 million, shareholders' equity of $6.5 million, and a net loss of -$7.1 million for the quarter [sec].
- The company has incurred recurring losses and negative operating cash flows, raising substantial doubt about its ability to continue as a going concern without additional funding [sec_mda · as of 2026-08-14].
- Lantern Pharma expects to require substantial additional funding in the near future to continue research and development activities [sec_mda · as of 2026-08-14].
What works
- Lantern Pharma's RADR® AI platform may enable more efficient identification of drug candidates and patient populations, potentially reducing development timelines and costs [sec_mda · as of 2026-03-30].
- The company has a pipeline of multiple clinical-stage candidates (LP-300, LP-184, LP-284) addressing different cancer types, providing diversification in its development efforts [sec_mda · as of 2026-05-15].
- Lantern Pharma plans to pursue periodic capital raises, collaborations, and grant funding to extend its operating runway, indicating active efforts to secure financing [sec_mda · as of 2026-08-14].
What to weigh
- Lantern Pharma has incurred recurring losses and negative operating cash flows, with a net loss of -$7.1 million in the most recent quarter, and expects losses to continue for several years [sec_mda · as of 2026-08-14] [sec].
- The company's cash position of $6.7 million as of June 30, 2026, is limited relative to its planned clinical development activities, and management has expressed substantial doubt about its ability to continue as a going concern without additional funding [sec_mda · as of 2026-08-14] [sec].
- There is no assurance that sufficient funding will be available when needed, and the company may use its available capital resources sooner than expected [sec_mda · as of 2026-08-14].
- The company is unable to estimate the exact amount of its operating capital requirements due to the numerous risks and uncertainties associated with pharmaceutical development [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
Substantial doubt about going concern
“These factors raise substantial doubt about our ability to continue as a going concern in the absence of obtaining substantial additional funding.”
SEC MD&A · August 14, 2026
Recurring losses and need for funding
“We have incurred, and anticipate that we will continue to incur, losses and generate negative operating cash flows and as such will require substantial additional funding in the near future to continue our research and development activities.”
SEC MD&A · August 14, 2026
Pipeline includes LP-300, LP-184, LP-284
“We expect to incur significant, fluctuating and often increasing operating losses at least for the next several years as we continue our clinical development of LP-300, LP-184 and LP-284, pursue development of our other drug candidates and programs”
SEC MD&A · May 15, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue as a going concern without additional funding [sec_mda · as of 2026-08-14]
- Limited cash runway — Cash of $6.7M as of June 30, 2026, may be insufficient to fund planned operations [sec] [sec_mda · as of 2026-08-14]
- No assurance of future funding — No guarantee that sufficient capital will be available when needed [sec_mda · as of 2026-08-14]
- Clinical development risks — Uncertainty in completing development and obtaining regulatory approval for drug candidates [sec_mda · as of 2026-03-30]
What to watch
- Ability to secure additional funding through capital raises, collaborations, or grants to extend operating runway [sec_mda · as of 2026-08-14]
- Progress of clinical trials for lead candidates LP-300, LP-184, and LP-284 [sec_mda · as of 2026-05-15]
- Changes in cash position and net losses in future quarterly filings [sec]
- Any updates on the company's going concern status or material changes in financial condition [sec_mda · as of 2026-08-14]
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Lantern Pharma Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Lantern Pharma Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
7.8 months
OCF -$3M · Net income -$7M
Lead: Phase 1/Phase 2
4 candidates
No upcoming catalysts tracked
2 buys · 0 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
29
Total value held
$2.8M
| Holder | Shares | Value |
|---|---|---|
| bios capital management, lp | 864,435 | $1.2M |
| vanguard capital management llc | 664,158 | $910K |
| renaissance technologies llc | 116,000 | $159K |
| geode capital management, llc | 111,646 | $153K |
| vanguard fiduciary trust co | 49,607 | $68K |
| blackrock, inc. | 45,267 | $62K |
| dimensional fund advisors lp | 38,060 | $52K |
| horizon kinetics asset management llc | 26,373 | $36K |
| davenport & co llc | 23,814 | $33K |
| state street corp | 23,652 | $32K |
Showing top 10 of 29 institutional holders of Lantern Pharma Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 15.5%
- Days to cover
- 1.2
- Shares short
- 1,741,042
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LTRN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Lantern Pharma Inc.?
Lantern Pharma Inc. (LTRN) is a clinical-stage biotechnology company focused on developing targeted cancer therapies using its proprietary AI-driven drug discovery platform, RADR®, with lead candidates LP-300, LP-184, and LP-284 in various stages of clinical development.
What is Lantern Pharma Inc.'s lead drug candidate?
Lantern Pharma Inc.'s most advanced tracked candidate is lp-100 (Phase 2) for Metastatic castration resistant prostate cancer (mCRPC).
Who is the CEO of Lantern Pharma Inc.?
Mr. Panna Sharma is the chief executive officer of Lantern Pharma Inc. (LTRN).
Where is Lantern Pharma Inc. headquartered?
Lantern Pharma Inc. (LTRN) is headquartered in Dallas, TX, United States.
What therapeutic areas does Lantern Pharma Inc. focus on?
Lantern Pharma Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.